The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.